MedTrace Logo

Neuroprotective Goal Directed Hemodynamic Optimization in Post-cardiac Arrest Patients

NCT02541591 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2024-04-12

Study results available
· View outcomes & findings →

Summary

The primary objective of the Neuroprotect trial is to assess whether or not a new goal directed hemodynamic optimization strategy can reduce cerebral ischemia in post-cardiac arrest (CA) patients.

Conditions

  • Cerebral Ischemia
  • Cardiac Arrest

Interventions

OTHER

Neuroprotective goal directed hemodynamic optimization

OTHER

MAP > 65mmHg

MAP \> 65mmHg

Sponsors & Collaborators

  • Ziekenhuis Oost-Limburg

    collaborator OTHER

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Koen Ameloot, MD · UZ Leuven

  • Stefan Janssens, MD · UZ Leuven

  • Joseph Dens, MD · Ziekenhuis Oost-Limburg

  • Cathy De Deyne, MD · Ziekenhuis Oost-Limburg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2018-06-30
Completion
2018-06-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02541591 on ClinicalTrials.gov